Exploring in vivo lesion myelination dynamics: Longitudinal Myelin Water Imaging in early Multiple Sclerosis

Hagen H Kitzler1, Hannes Wahl1, Paul Kuntke1

  • 1Institute of Diagnostic and Interventional Neuroradiology, Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany.

Neuroimage. Clinical
|September 26, 2022
PubMed
Abstract

Insights

Multiple Sclerosis (MS) lesions show variable myelination changes over time. Myelin Water Imaging (MWI) reveals individual lesion patterns, suggesting repeated demyelination and remyelination in early MS for personalized treatment monitoring.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarker Discovery

Background:

  • Multiple Sclerosis (MS) lesions exhibit pathological heterogeneity and variable temporal myelination changes, particularly in early disease stages.
  • Monitoring individual lesion myelination using quantitative Myelin Water Imaging (MWI) can reveal disease variability and subclinical activity.

Purpose of the Study:

  • To observe in vivo lesion myelination variation and longitudinal changes using MWI and Myelin Water Fraction (MWF).
  • To identify individual myelination patterns in early MS lesions.

Main Methods:

  • 12 early MS patients underwent quantitative MWI (mcDESPOT) at four time-points over 12 months.
  • Lesion tracking (AFIL algorithm) and evaluation of lesion volume and MWF were performed.
  • MWF change defined lesion categories: decreasing, varying, increasing, and invariant.

Main Results:

  • 386 T2 lesions were detected; 225 were permanent across all time-points.
  • Heterogeneous MWF reduction was observed, with most lesions showing mild reduction.
  • Permanent lesions displayed variable dynamics (58% varying MWF), with distinct subgroups reflecting demyelination and remyelination.

Conclusions:

  • In vivo MWI provides evidence for individual evolution of early demyelinated MS lesions.
  • Results support multiple demyelination/remyelination episodes in early MS.
  • MWF imaging serves as a potential novel biomarker for personalized MS treatment selection and monitoring.

Related Concept Videos